FDA approves Implantica RefluxStop for US
Analysis based on 17 articles · First reported Aug 20, 2026 · Last updated Aug 21, 2026
The FDA approval opens the U.S. market for Implantica's RefluxStop, potentially driving significant revenue growth and enhancing the company's valuation. The news is likely to positively impact Implantica's stock price and investor sentiment, while also increasing competition in the GERD treatment market.
Implantica AG, a Liechtenstein-based medtech company, announced on August 20-21, 2026, that the U.S. United States — Food and Drug Administration (FDA) granted Premarket Approval (PMA) for RefluxStop, its implant-based treatment for gastroesophageal reflux disease (GERD). The approval allows Implantica to begin commercial launch in the United States, the world's largest medical device market. RefluxStop is designed to restore the natural anatomy of the gastroesophageal junction without encircling the esophagus, avoiding common side effects of conventional anti-reflux surgery. The approval follows FDA review of long-term clinical evidence supporting 5-year safety and effectiveness. Implantica already has commercial experience in Europe with nearly 1,800 patients treated across more than 60 Centers of Excellence in nine countries. CEO Peter Forsell highlighted the substantial growth opportunity in the U.S., where an estimated 78 million people suffer from acid reflux. The initial U.S. rollout will be targeted at leading centers and reflux surgeons, with adoption expected to build gradually. Implantica is listed on Nasdaq First North Premier Growth Market in Stockholm.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard